I've completed the deep research on the neurotech landscape you requested. Here’s the breakdown:
1. Merge Neurotech / Merge BCI
Merge Labs is a high-profile BCI startup that recently emerged from stealth mode as a spin-out from Forest Neurotech.
Founders: Co-founded by Sam Altman (OpenAI), Alex Blania (Worldcoin), Sumner Norman, and Tyson Aflalo.
Status: Reportedly seeking to raise $250M at an $850M valuation, with expected backing from OpenAI Ventures.
Approach: They are pursuing a non-invasive or minimally invasive approach using functional ultrasound (fUS) technology, aiming for high-resolution brain reading without the risks of open-brain surgery.
2. Non-Invasive Competitors & BCI Landscape
While BlackRock Neurotech leads in invasive BCIs (e.g., the Utah Array), the non-invasive sector is rapidly expanding.
Competitors: Key players include Kernel (fNIRS), Neurable (EEG-integrated headphones), Emotiv, Bitbrain, and OpenBCI.
Market Share: Non-invasive BCIs currently hold approximately 87.5% of the market revenue share due to safety and accessibility.
Trade-offs: Invasive systems offer superior signal precision (single-neuron recording) but carry surgical risks and face long-term stability issues (gliosis). Non-invasive systems are safer for mass-market adoption but suffer from signal attenuation by the skull.
3. Bone Acoustic Information Development
This research focuses on transmitting sound vibrations through the skull directly to the cochlea, bypassing the outer ear.
BCI Integration: Bone conduction is being explored as a "silent" feedback channel for BCIs, allowing users to receive information through vibrations perceived as sound.
Neural Communication: It is highly effective in noisy environments (military/aviation) and is being studied for its ability to stimulate the vagus nerve and enhance neuroplasticity in hearing rehabilitation.
4. Failed & Discontinued Projects (Arxiv/GitHub)
The field has seen several notable failures due to technical, financial, and regulatory hurdles.
Notable Failures: Cyberkinetics (original BrainGate), Second Sight (Argus II), and NeuroVista.
Technical Reasons: Common issues include signal degradation over time due to the body's immune response, hardware obsolescence (unsupported drivers), and the "orphan device" crisis where patients are left with unsupported implants after a company's bankruptcy.
Lessons Learned: Post-mortems on Arxiv and GitHub emphasize the need for standardized data formats and more sustainable business models to navigate the long FDA approval process.